The following article is a part of conference coverage from Psych Congress 2021 , held October 29th through November 1, 2021, in San Antonio, Texas. The team at Psychiatry Advisor will be reporting on the latest news and research conducted by leading experts in psychiatry. Check back for more from the Psych Congress 2021.

 

A retrospective analysis of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) found that Jornay PM (DR/ER-MPH) decreased ADHD symptoms compared with placebo and was associated with a positive growth trajectory. These findings were presented during Psych Congress 2021 held in San Antonio, Texas, from October 29 to November 1, 2021.


Continue Reading

A previously published phase 3 trial reported positive outcomes with DR/ER-MPH, a delayed-release/extended-release methylphenidate therapy. In order to determine whether these findings could be replicated in a real-world setting, a researcher from Austin Regional Clinic in Texas retrospectively assessed patient (N=30) records of individuals with ADHD who had at least 3 months of DR/ER-MPH use. Patients were assessed for dosage, changes to parent- and patient-reported ADHD symptoms, and growth.

Patients were 30% girls and aged mean 12.8 (standard deviation [SD], 3.1) years; 70% had received stimulant treatment previously, 87% had at least 1 psychiatric comorbidity, and 76% were on at least 1 concomitant psychotropic medication.

Patients had a starting DR/ER-MPH dose of 20 (40%), 40 (43%), 60 (10%), and 80 (7%) mg. The average optimum dosage was 70.7 (range, 40-100) mg/d.

Patients reported improved focus (n=29), decreased side effects (n=18), improved grades (n=8), improved mornings (n=8), decreased impulsivity (n=3), and improved duration (n=2).

Among the 28 patients who reported eating behaviors, 26 said they were eating normally, 1 ate “lots,” and 1 ate less. For the 13 who reported appetite patterns, 6 said their appetite increased, 5 had a normal appetite, and 2 said their appetite decreased.

The median z-scores for weight increased from a median of 0.38 (interquartile range [IQR], -0.16 to 1.06) at baseline to 0.71 (IQR, -0.31 to 1.50) after the DR/ER-MPH dose was optimized. Z-scores for height increased from 0 (IQR, -0.32 to 0.92) to 0.05 (IQR, -0.32 to 0.92).

This study was limited by its single center, retrospective design.

These data confirmed findings from a phase 3 trial in which pediatric patients with ADHD had favorable changes to symptoms and positive growth trajectories after receiving treatment with JORNAY PM.

Disclosure: The study was sponsored by Ironshore Pharmaceuticals and Development, Inc.

 

Visit Psychiatry Advisor’s meetings section for complete coverage of Psych Congress 2021.

 

Reference

Anderson JC. Early integration of delayed-release/extended-release methylphenidate (JORNAY PM®) into a pediatric practice: retrospective electronic medical record analysis of children and adolescents with ADHD. Poster presented at: Psych Congress 2021, October 29-November 1, 2021; San Antonio, Texas. Poster 3.